Presentation:  4:00-5:00PM
Discussion & Reception: 5:00-6:00PM

Presentation at MGH: Haber Room
Videoconference to DFCI: Jimmy Fund, Room 836 (Please note: This is NOT at Dana 1620)

Representatives from Boehringer Ingelheim:

Wolfgang Rettig, MD, PhD, Senior Vice President Research
Gerd Stehle, Therapeutic Area Head Oncology
Andree Amelsberg, MD, MBA, Executive Director Oncology

Topics/Compounds to be presented:

• Overview of Oncology Drug Discovery Research & Clinical Research
  
• BIBW 2992 - Dual, Irreversible EGFR/HER2 inhibitor
  
• BIBF 1120 - Triple Angiokinase inhibitor
  
• BI 2536 - First-in-class PLK1 inhibitor
  

Note: Presentations are designated for DF/HCC members only and are not open to the public.

If you would like a 1:1 meeting with Boehringer Ingelheim, or for more information please contact Petra Loesch at 617-724-3867 or ploesch@partners.org.